|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Geron Corporation (GERN) And Exeter Life Sciences, Inc. Form Joint Venture For Licensing Animal Cloning Technologies
10/19/2005 5:13:13 PM
MENLO PARK, Calif. & PHOENIX--(BUSINESS WIRE)--April 6, 2005--Geron Corporation (Nasdaq:GERN) and Exeter Life Sciences, Inc. announced today the formation of stART Licensing, Inc., a new company that will manage and license a broad portfolio of intellectual property rights related to animal reproductive technologies. This unique portfolio includes the foundational nuclear transfer cloning technology that was developed at the Roslin Institute for the cloning of Dolly the sheep.
Through the creation of the stART Licensing joint venture the leading intellectual property for animal cloning, including the full breadth of rights under the Roslin technology, will be combined under one roof.
Geron is contributing patent rights to stART, including rights to the Roslin technology and patents to related developments arising from animal cloning work that Geron funded at the Roslin Institute. Exeter is contributing rights acquired from PPL Therapeutics, Inc. to use the Roslin technology for producing proteins in milk of animals, as well as rights to other cloning technologies, including chromatin transfer, a technology developed at the University of Massachusetts. Exeter will provide initial capital for the company's operations, as well as management services. Geron and Exeter will hold 49.9% and 50.1% stakes in stART, respectively. In addition, Geron will receive up-front cash and milestone payments. Geron and Exeter will receive distributions of profits from stART proportionate to their equity interests.
|
|
|
|
|
|
|
|
|
|
|